Skip to content
160. ASCO 2025 - Plenary Part 2 episode artwork

Jun 11, 2025 25 min

160. ASCO 2025 - Plenary Part 2

from Oncology for the Inquisitive Mind

In our second plenary episode, we're spotlighting two pivotal phase 3 trials: SERENA-6, which explores ctDNA-guided treatment with camizestrant to delay progression in HR-positive, HER2-negative advanced breast cancer with ESR1 mutations, and NIVOPOSTOP, a landmark study showing improved disease-free survival with adjuvant nivolumab in high-risk, resected head and neck squamous cell carcinoma. Join us as we unpack these practice-changing findings with expert insight and a couple of dad jokes along the way. Studies discussed in the episode: SERENA-6 NIVOPOSTOP For more episodes, resources and blog posts, visit www.inquisitiveonc.com Please find us on Twitter @InquisitiveOnc! If you want us to look at a specific trial or subject, email us at [email protected] Art courtesy of Taryn Silver Music courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/ Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice. Oncology for the Inquisitive Mind is recorded with the support of education grants from our foundation partners Pfizer, Gilead Pharmaceuticals and Merck Pharmaceuticals. Our partners have access to the episode at the same time you do and have no editorial control over the content.

Episode details come from the podcast's RSS feed.

Embed this episode

Ready to play

160. ASCO 2025 - Plenary Part 2

0:00 25:44

No transcript yet.

Requests help us decide what to transcribe next.

Frequently asked questions

How long is this episode of Oncology for the Inquisitive Mind?

This episode is 25 minutes long.

When was this Oncology for the Inquisitive Mind episode published?

This episode was published on June 11, 2025.

Can I download this Oncology for the Inquisitive Mind episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.